%D8%B3%D9%8A%D9%83%D9%84%D9%88%D9%81%D9%88%D8%B3%D9%81%D8%A7%D9%85%D9%8A%D8%AF%D8%B3%DB%8C%DA%A9%D9%84%D9%88%D9%81%D8%B3%D9%81%D8%A7%D9%85%DB%8C%D8%AFCategory:CyclophosphamideCyklofosfamidCycloffosffamidCyclophosphamidCyclophosphamideCiclofosfamida%D8%B3%DB%8C%DA%A9%D9%84%D9%88%D9%81%D8%B3%D9%81%D8%A7%D9%85%DB%8C%D8%AFSyklofosfamidiCyclophosphamideCioglafosfaim%C3%ADdCiclofosfamidaCiklofoszfamid%D5%91%D5%AB%D5%AF%D5%AC%D5%B8%D6%86%D5%B8%D5%BD%D6%86%D5%A1%D5%B4%D5%AB%D5%A4Ciclofosfamide%E3%82%B7%E3%82%AF%E3%83%AD%E3%83%9B%E3%82%B9%E3%83%95%E3%82%A1%E3%83%9F%E3%83%89%EC%8B%9C%ED%81%B4%EB%A1%9C%ED%8F%AC%EC%8A%A4%ED%8C%8C%EB%AF%B8%EB%93%9C%E0%B4%B8%E0%B5%88%E0%B4%95%E0%B5%8D%E0%B4%B2%E0%B5%8B%E0%B4%AB%E0%B5%8B%E0%B4%B8%E0%B5%8D%E0%B4%AB%E0%B4%BE%E0%B4%AE%E0%B5%88%E0%B4%A1%E0%B5%8DCyclofosfamide%E0%AC%B8%E0%AC%BE%E0%AC%87%E0%AC%95%E0%AD%8D%E0%AC%B2%E0%AD%8B%E0%AC%AB%E0%AC%B8%E0%AC%AB%E0%AC%BE%E0%AC%AE%E0%AC%BE%E0%AC%87%E0%AC%A1Cyklofosfamid%D8%B3%D8%A7%D9%8A%DA%A9%D9%84%D9%88%D9%81%D9%88%D8%B3%D9%81%D9%85%D8%A7%D9%8A%DA%89CiclofosfamidaCiclofosfamid%C4%83%D0%A6%D0%B8%D0%BA%D0%BB%D0%BE%D1%84%D0%BE%D1%81%D1%84%D0%B0%D0%BC%D0%B8%D0%B4CiklofosfamidCyclophosphamideCiklofosfamidCiklofosfamidCyklofosfamidCyclophosphamide%D0%A6%D0%B8%D0%BA%D0%BB%D0%BE%D1%84%D0%BE%D1%81%D1%84%D0%B0%D0%BC%D1%96%D0%B4CyclophosphamideQ408524%E7%8E%AF%E7%A3%B7%E9%85%B0%E8%83%BA
about
Burkitt lymphomachronic lymphocytic leukemiaEwing's sarcomagranulomatosis with polyangiitisbreast cancersystemic lupus erythematosuslupus nephritisovarian cancerendometrial carcinomabreast carcinomalung benign neoplasmfamilial retinoblastomaHodgkin's lymphoma, mixed cellularitylymphosarcomamycosis fungoidesrhabdomyosarcomahemosiderosisdiffuse large B-cell lymphomaacute myeloid leukemiaautoimmune hemolytic anemiatesticular cancermacroglobulinemiamultiple myelomaretinoblastomanephrotic syndromeenthesopathyautoimmune thrombocytopenic purpuralymphoid leukemiachronic myeloid leukemiapure red-cell aplasiamultiple sclerosismyasthenia gravisprimary angiitis of the central nervous systemneuroblastoma
P2176
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerPilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasNivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerHigh Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseMatched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous DiseaseA Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyA Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaUse of Dexamethasone in Pediatric Asthma ExacerbationsBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaPomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaAutologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaEvaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaMLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaPhase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceMLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaBelatacept in Kidney Transplantation of Moderately Sensitized PatientsUARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionE GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL CCytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell TransplantSIMPLE Chemotherapy for NK Lymphoma/LeukaemiaDA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLIxazomib Maintenance Study in Patients With AL AmyloidosisPre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After CraniotomyEfficiency of IV Dexamethasone, Administered After a Lower Limb Blockade, on the Post Operative Pain in ChildrenTrial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsVaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaThe Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD TherapyDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsEffect of Topical Tetracycline and Dexamethasone on Periodontal and Pulpal Regeneration of Replanted Avulsed TeethDexamethasone Versus Dexmedetomidine as Adjuvants for Nerve BlocksDexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML)Adjuvant Palbociclib in Elderly Patients With Breast CancerDexamethasone Effect in the Reduction of Macular Thickness in Diabetic PatientsA Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-centerIontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics
P4844
Micronuclei assay in cytokinesis-blocked binucleated and conventional mononucleated methods in human peripheral lymphocytes.Review of experimental male-mediated behavioral and neurochemical disorders.Evaluation of Drosophila for screening developmental toxicants: test results with eighteen chemicals and presentation of a new Drosophila bioassay.Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology wardA comparison of baseline and cyclophosphamide-induced sister chromatid exchanges in bone marrow and spleen cells of mouse and chinese hamsterComparative in vivo and in vitro sister chromatid exchange studies in chinese hamster bone marrow and spleen cellsCyclophosphamide-induced cytogenetic effects in mouse bone marrow and spleen cells in in vivo and in vivo/in vitro assaysPreparation of mouse bone marrow primary cultures for sister chromatid exchange and chromosomal aberration studiesIn vivo and in vivo/in vitro kinetics of cyclophosphamide-induced sister-chromatid exchanges in mouse bone marrow and spleen cellsInduction of micronuclei in BALB/c-3T3 cells by selected chemicals and complex mixturesSampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environmentEvaluation of chemotherapy drug exposure at a veterinary teaching hospital in MichiganSister-chromatid exchange studies on direct- and indirect-acting clastogens in mouse primary cell culturesReduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device3-Hydroxypropylmercapturic acid: a biologic marker of exposure to allylic and related compoundsDevelopment of an HPLC method for simultaneous analysis of five antineoplastic agentsA new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agentsA study of occupational exposure to antineoplastic drugs and fetal loss in nursesEffects of ethylene glycol monomethyl (EGME) and monoethyl (EGEE) ethers on the immunocompetence of allogeneic and syngeneic mice bearing L1210 mouse leukemiaMonitoring method for surface contamination caused by selected antineoplastic agentsSurface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studiesHealth hazard evaluation report: HETA-2011-0047-3143, multiple sclerosis cluster evaluation in an inpatient oncology ward - WisconsinHealth hazard evaluation report: HETA-2010-0118-3142, chemotherapy drug evaluation at a medical laboratory - PennsylvaniaExternal contamination of chemotherapy vialsLista de NIOSH de antineoplásicos y otros fármacos tóxicos en entornos de atención médica, 2010Evaluation of a test method for the measurement of urinary cyclophosphamide, 4-ketocyclophosphamide and ifosfamideHealth hazard evaluation report: evaluation of chemotherapy drug exposure in an outpatient infusion centerHealth hazard evaluation report: HETA-2009-0148-3158, chemotherapy drug exposures at an oncology clinic - FloridaHealth hazard evaluation report: HETA-2010-0068-3156, chemotherapy drug evaluation at a veterinary teaching hospital - MichiganToxic substances and congenital malformationsInvestigation of Drosophila for Teratogenic ScreeningInhibition of cyclophosphamide and mitomycin c-induced sister chromatid exchanges in mice by vitamin cInteraction Between Normal Human Diploid Cells And Chemical Carcinogens/Mutagens In VitroNIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2010 (superseded by 2012-150)Characterization and Validation of Carcinogen-Induced Transformation of Human Cells In VitroUrinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamideCyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion.Experimental rabies in skunks: effects of immunosuppression induced by cyclophosphamide.Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario.Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.
P921
Q1016605-BC8BD008-2E5C-4501-BBA8-DABDDEC3D4B8Q1016605-BE01D8A3-6820-427D-B678-9109B258AAFDQ1088156-9413AFEC-C1CF-41E0-85EF-4BD37F6FC194Q1088156-9B502BB2-1EF6-4049-AE6D-DA7BAB9C414FQ1138580-593821AE-6E03-49E0-8952-B25F78EA29B9Q1161568-219E5DFA-6563-4AEF-BE5A-C39EE1B20C5EQ128581-DB8CE325-269E-4CEB-8BB9-58170BDFD2E9Q1485-888CEDA4-B8CA-4329-966E-65EFB9785543Q1621830-691056E4-DAEB-47CA-B7AC-53F5DAAEA32FQ172341-37E7F309-ADC2-45BC-8F56-8EAF40AE5722Q172341-5803EF3E-2676-4ECB-A1AC-1DE303B4CB69Q18555222-0B552EE1-6A41-4B7B-8D4C-D72D59CFC68DQ18555947-9018D45E-3217-4B4E-A663-A0D20537A4CEQ18556020-8CDD68E9-B7CD-41E8-A940-DF984E7CD624Q18556413-0D8B8322-6587-4340-AACB-AE63B5A59215Q18557991-426C0592-BE6D-4236-AE8F-886B4C4A486AQ18557991-67FE1CEA-A6EF-4036-A63D-D279F2FA2476Q18557998-0586C0D2-4B9A-41C8-A21B-B210227F9E67Q1891209-638D42C9-E03C-4BC5-B199-C8E029171E3CQ1891209-E314753C-C0CD-4DDA-86B7-BE5675594A60Q1898141-B3374DF1-07A1-433C-BEF4-2F3633EF2207Q2089854-65B76606-6B10-44EC-AC39-FE13CA788D36Q2626074-FF2043CE-2C3C-497A-8E41-FDF222E91C56Q264118-311C83BD-B6B5-4059-BABB-E2A775CE0B27Q28814-FE059EA7-DE58-4698-91E7-F59827C35EADQ324464-3788FABE-45CC-411C-885E-F306625DF828Q4118092-7A31F453-C5BB-4E1B-9EE5-236EF016D486Q467635-D562E3D6-95CE-4BF4-A436-366F9B4E8792Q467635-E6743D7B-04B0-41D2-98CC-C7F5C261EB11Q500695-CAD626C4-B58D-48EE-BB24-4DD96B6B2C53Q504790-59E23E5A-A80F-4535-84E6-9F39AC1DEDE0Q504790-6B24774C-E108-4B50-8F38-2C6486DCAD3EQ52844-04D3AEDF-A32B-42E4-86F8-85BEC9A1ED89Q638729-4D58163D-370B-4B22-839A-6BF7AC570240Q6708277-B9CD057A-719F-46A1-8A8F-459E4185265AQ729735-E82C27EC-3182-41E8-B317-B05FE37D8677Q751631-0283F205-1539-41CE-B9BD-07B9851FCEF1Q8277-9BCBD2D4-6B7F-4EB8-AEFD-47D05730E50EQ8285-203F4473-4216-4BDF-AF2F-40FC3F94FE1CQ93333268-1eb94428-4e8d-f217-3056-c2a5a940a9db
P2176
Q58407406-32725c29-40a0-9e22-4311-cdb0063843ffQ58407540-11005A7B-C33E-4091-AD55-AF1588B9633EQ58846466-f45d69df-4a13-7bf2-2663-865db764ceebQ60502449-EEFD1C9D-59BD-4F56-8A3B-C256C1580393Q60502469-33E972B4-C7A5-477C-8A94-17ECF7054942Q61700075-08C4FDFE-B543-4828-97CD-783CF5DBE03FQ61862177-430F41B8-06C7-4852-AD2B-B176CB145B7CQ61862210-3139308A-E350-4135-A5C3-A64EAD63B609Q61862227-E6ACE754-A2DA-4EA9-884A-809F7F3DE461Q61862239-3A1C31CB-D19A-4D59-90A3-34EF2142FFAFQ61864731-DA9EEB16-DB26-4E45-8242-9226F1E13208Q61864749-9274805F-EA1F-4242-8011-E8545CF6268EQ61864779-2E7F9D58-41E4-4510-AD0C-32A0BF0B7F1BQ61864815-93D627F8-A312-4F1C-9DB7-20D568D05329Q61864842-BBE7D324-2B50-4CA0-80EE-03521F5A6F6CQ61864847-22114A96-E6D9-4941-AC5E-BC0EDFD93947Q61864849-D2D22062-4A9C-47CF-9487-CD67544BA46FQ61864899-D06C8D4B-CBAC-4BE2-AB4F-CDF1CD877AC9Q61894370-FE5E5285-051D-4ACB-9D57-CF500871D68EQ61894570-F4F30D57-7A82-4681-B884-EAD4B44F38E1Q61902360-0ADD652E-6A36-4155-BFD7-1C428F5D3B93Q61902423-5E90095F-CBA9-4E05-9B34-D9B9638AAB0FQ61902425-1981A219-6565-42E8-85FC-FCC062836037Q61902671-794B1883-CBFE-489F-B145-D3D194E4B2B5Q61902862-632B03A2-F3BE-41E5-93B6-9D16801CF8F2Q61904680-891A689C-6948-4B8C-AED9-6A9671A30220Q61904688-8D3CB0E6-96A6-4262-96F5-3B29CEABFAEFQ61904718-05B11E57-DEEC-4E4E-B707-ECA6DA33C9CFQ61904758-DF1749BE-2539-4279-BD03-6272B2CF2866Q61904766-4044283E-14A4-4E49-80F5-0210BBD4C1C8Q61904908-514F6A68-5CD9-4612-AE4C-3104D32FBFDEQ61904952-422F54BE-A2EB-4E3F-8C93-D07A281421D5Q61906744-E7CC0447-FA02-4AAD-994C-7571CEDA521DQ61906839-B9F52963-EB89-414B-B67D-6873E0750185Q61906991-823F776E-CCE7-41A6-BABE-5BA976B8F0DFQ61906992-FED1AEAF-6948-4E69-9AB8-2C628197F149Q61907011-8F189C00-6B97-4DE5-8071-FFBC44E40E69Q61907040-D6BCDA7E-9E34-49CD-B3B1-771A00C8053EQ61907080-27F207E4-C2E1-4B30-B03C-4328C8242F89Q61907170-53FF3E86-ED60-4161-861D-EE8187AB0BF2
P4844
Q23909191-1BA43B0C-3C29-4562-934C-6C8EC464B303Q23910242-D76763E3-E13F-4545-9715-6672227B4C45Q23912049-A498BF61-62A6-4CD1-93F9-11692B2AB048Q23912471-1BE9A93C-C40E-4542-A3F2-22EACEDDC97DQ23912945-20A5288C-1F9B-41B5-9D6E-79D923FF4EB1Q23912946-4C378728-26FE-4C86-8443-31B1D9E78E18Q23912947-B429AFE0-A654-45FE-8836-92AAE37D8FE2Q23912949-F5AB7198-08A3-4318-979E-69837782F154Q23912955-1449A31F-97AF-4679-BF82-4C6E1FB55B69Q23913272-E8CAE5FF-CE67-4846-81EC-8F4045808E35Q23914149-D8B48351-F900-448C-94EB-9760EB01ABA5Q23914231-3EED0701-E73E-4E8C-9C0B-B5DBAD6E1478Q23916606-2822B8FC-3428-489F-9958-E03BC2C3CD01Q23919324-CD9C746E-0499-4670-A51A-01F4F2CB3447Q23919889-1DCC0B15-D61A-4B7E-8456-5C863C938EBEQ23920413-DCDCD5B2-10BB-4D0D-8371-24844206C935Q23920414-00A8F06B-ABEB-418E-85FC-5AE9D54042FCQ23921339-BE8676E0-209F-4D07-AB04-06B51E2EB80FQ23922827-AA78371B-923D-425B-926D-F01E9587A330Q23923245-7B91DC3C-4F1C-4D6B-94B1-B834B51E98C8Q23923320-852EE45E-B292-45A3-9B8C-402191528500Q24266781-47140DD6-7A44-41AB-A1C3-D9E2396E71C6Q24353376-EAD3095A-587C-4BBD-B3EE-80218358DC5EQ24704561-3FC24670-7CF5-4005-BD68-D4657D2540E4Q24706974-C13F5337-34E2-41CA-B4BA-EF6BE0B29A47Q24849676-7363249E-92F9-4F2E-95DF-1D41CD99B163Q24977607-7540B1AA-6553-40B6-A42C-A5079CF09441Q25018194-5DA7A3CB-2595-46B4-AD52-EC5395D6ACD3Q25892070-4961BE5E-F3DD-41BF-ACF9-7E804E2E538EQ26324660-58560333-C8DD-4A38-9953-782EB5E6E378Q26330676-5C35C220-E717-447D-99C2-5CBB2582627AQ26343210-3681F87F-BA98-4619-83C6-42C666ABD2B7Q26373926-17A95B39-64D8-4405-9B69-3A965B642DE9Q26376049-A34DE0C8-1BF7-4C95-9573-F6F38B787F6EQ26376209-FFD32C2A-AAC4-45C5-A526-BB7C1CD3B9AEQ27987294-b5324f3a-4067-bf91-0228-476eb740ac1aQ33282121-D3D6F429-5332-4751-9147-6C2C9B7362F7Q34046067-08b2e9c8-491d-5e4f-5680-e0a7f2953407Q42963326-176c4b0a-4f2c-639f-0b49-cc1ed3b66300Q45084231-1d32cdca-4f60-a26f-d96f-80ee362d90fb
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ciclofosfamida
@gl
Ciclofosfamide
@it
Ciclofosfamidă
@ro
Ciklofosfamid
@sh
Ciklofosfamid
@sl
Ciklofosfamid
@sr-el
Ciklofoszfamid
@hu
Cioglafosfaimíd
@ga
Cyclofosfamide
@nl
Cyclophosphamid
@de
type
label
Ciclofosfamida
@gl
Ciclofosfamide
@it
Ciclofosfamidă
@ro
Ciklofosfamid
@sh
Ciklofosfamid
@sl
Ciklofosfamid
@sr-el
Ciklofoszfamid
@hu
Cioglafosfaimíd
@ga
Cyclofosfamide
@nl
Cyclophosphamid
@de
altLabel
(+-)-Cyclophosphamide
@cy
(+-)-Cyclophosphamide
@en
(RS)-Cyclophosphamide
@cy
(RS)-Cyclophosphamide
@en
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
@cy
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
@en
50-18-0
@fr
Anhydrous cyclophosphamide
@en
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
@cy
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
@en
prefLabel
Ciclofosfamida
@gl
Ciclofosfamide
@it
Ciclofosfamidă
@ro
Ciklofosfamid
@sh
Ciklofosfamid
@sl
Ciklofosfamid
@sr-el
Ciklofoszfamid
@hu
Cioglafosfaimíd
@ga
Cyclofosfamide
@nl
Cyclophosphamid
@de